相似文献
1
Safety of tofacitinib in IBD: A tricky puzzle.
United European Gastroenterol J. 2024 Jul;12(6):658-659. doi: 10.1002/ueg2.12587. Epub 2024 May 18.
2
The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
J Crohns Colitis. 2017 Jul 1;11(7):885-893. doi: 10.1093/ecco-jcc/jjx003.
3
Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis.
World J Gastroenterol. 2024 Sep 14;30(34):3929-3931. doi: 10.3748/wjg.v30.i34.3929.
4
Update on Janus kinase antagonists in inflammatory bowel disease.
Gastroenterol Clin North Am. 2014 Sep;43(3):603-17. doi: 10.1016/j.gtc.2014.05.011. Epub 2014 Jun 24.
5
Safety and Effectiveness of Janus Kinase Inhibitors in the Management of Inflammatory Bowel Disease Following Liver Transplantation.
J Crohns Colitis. 2024 Sep 3;18(9):1505-1509. doi: 10.1093/ecco-jcc/jjae039.
6
Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study.
BMC Gastroenterol. 2024 Aug 19;24(1):273. doi: 10.1186/s12876-024-03336-2.
7
The use of tofacitinib in the treatment of inflammatory bowel disease.
Immunotherapy. 2018 Aug;10(10):837-849. doi: 10.2217/imt-2018-0015. Epub 2018 Apr 27.
8
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.
United European Gastroenterol J. 2024 Jul;12(6):793-801. doi: 10.1002/ueg2.12584. Epub 2024 May 22.
9
Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
Dig Dis Sci. 2019 Jul;64(7):1945-1951. doi: 10.1007/s10620-019-05492-y. Epub 2019 Feb 7.
10
The use of Tofacitinib in the treatment of inflammatory bowel disease.
Ter Arkh. 2019 Mar 18;91(2):101-108. doi: 10.26442/00403660.2019.02.000155.
本文引用的文献
1
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.
United European Gastroenterol J. 2024 Jul;12(6):793-801. doi: 10.1002/ueg2.12584. Epub 2024 May 22.
2
Histologic Activity in Inflammatory Bowel Disease and Risk of Serious Infections: A Nationwide Study.
Clin Gastroenterol Hepatol. 2024 Apr;22(4):831-846. doi: 10.1016/j.cgh.2023.10.013. Epub 2023 Oct 30.
3
Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis.
Front Immunol. 2022 Sep 30;13:978203. doi: 10.3389/fimmu.2022.978203. eCollection 2022.
4
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927.
5
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.
Ann Rheum Dis. 2022 Jun;81(6):798-804. doi: 10.1136/annrheumdis-2021-221915. Epub 2022 Jan 13.
6
Risk of acute arterial events associated with treatment of inflammatory bowel diseases: a nationwide Danish cohort study.
Gut. 2022 Nov;71(11):2373-2374. doi: 10.1136/gutjnl-2021-326462. Epub 2022 Jan 11.
7
Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines.
United European Gastroenterol J. 2019 Nov 14;8(3):303-313. doi: 10.1177/2050640619889763. Print 2020 Apr.
8
Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study.
Gut. 2020 May;69(5):852-858. doi: 10.1136/gutjnl-2019-318932. Epub 2019 Aug 24.
9
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Inflamm Bowel Dis. 2018 Sep 15;24(10):2258-2265. doi: 10.1093/ibd/izy131.
10
Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention.
Inflamm Bowel Dis. 2018 Sep 15;24(10):2173-2182. doi: 10.1093/ibd/izy150.
Zotero 插件